Haima Therapeutics, a pre-clinical biotechnology company focused on developing platelet-inspired therapies to mitigate bleeding dysfunctions, announced today the appointment of Wolfgang Bergmeier to its Scientific Advisory Board (SAB). Dr. Bergmeier is a world-renowned scientist and key opinion leader in platelet biology, hemostasis, and thrombosis. He is currently a Professor of Biochemistry and Biophysics at The University of North Carolina School of Medicine.

“It is a pleasure to join Haima’s SAB. The SynthoPlate product is very promising and I hope to support its pre-clinical and clinical development” Bergmeier said. “Furthermore, I am excited about the future potential of the pipeline of platelet-inspired technologies that Haima is developing and look forward to providing scientific insight and technical support for their programs.”

“It is exciting to have Dr. Bergmeier join Haima’s SAB ” said Dr. Anirban Sen Gupta, Chair of the Scientific Advisory Board and Chief Scientific Adviser for the company. “Dr. Bergmeier’s vast expertise and insight in platelet biology, platelet dysfunctions and in vivo models can significantly advance the company’s R&D and translational endeavors in platelet-inspired technologies.”

“Dr. Bergmeier brings the platelet biology expertise needed to support the development of SynthoPlate, our lead program, in addition to providing technical guidance on our future platelet-inspired technologies under development.” said Dr. Michael Bruckman, Haima’s CEO. “He has proven to be a great collaborator during our first Small Business Innovation Research Award from the National Institutes of Health, and we are excited to have him on our SAB to help shape the future of Haima.”

Wolfgang Bergmeier, PhD
Wolfgang Bergmeier, PhD

About Wolfgang Bergmeier

Wolfgang Bergmeier, PhD, is a biomedical researcher working in the fields of signal transduction, platelet biology, and hemostasis and thrombosis. He studied biology at the University of Regensburg in Germany and graduated from Witten-Herdecke University, Department of Molecular Oncology, in 2001.

For his postdoctoral studies, Dr. Bergmeier joined the laboratory of Dr. Denisa Wagner at Harvard Medical School (HMS). In 2004 he was promoted to Instructor of Pathology at the HMS. During his time there, Dr. Bergmeier studied the molecular mechanisms leading to platelet damage during extended storage and to platelet adhesion at sites of vascular injury.

In 2007, he moved to Thomas Jefferson University in Philadelphia where he became an Assistant Professor of Medicine and a member of the Cardeza Foundation for Hematologic Research. During his time in Philadelphia, he built an externally funded research program that investigates signaling transduction pathways critical for platelet function in hemostasis.

In 2011 Dr. Bergmeier moved his research program to the University of North Carolina at Chapel Hill. He is a Professor of Biochemistry and Biophysics and a member of the Blood Research Center, both in the UNC School of Medicine. His lab identified the small GTPase Rap1 and its regulators as a unique Rheostat for platelet reactivity, both in circulation and at sites of vascular injury. His ongoing work focuses on a better understanding of the Rap1 signaling pathway in platelets and megakaryocytes, and the implementation of his findings for the development of improved anti-platelet therapies.

Dr. Bergmeier has over 120 publications and 6 book chapters with an impressive H-Index of 52 based on the research he has conducted.

About Haima Therapeutics

 Haima Therapeutics is a pre-clinical stage biotechnology company developing platelet-inspired technologies for the treatment of a variety of blood-related diseases. Haima’s initial focus is on platelet’s primary responsibility, hemostasis, wherein they are developing bio-inspired therapies to mitigate bleeding in multiple therapeutic indications, including traumatic injury, surgery, and thrombocytopenia. Haima’s lead product is called SynthoPlate, a novel, fully-synthetic hemostatic technology that mitigates bleeding by acting at the site of injury and amplifying your body’s natural clotting mechanisms.

news courtesy of www.haimatherapeutics.com